Publication
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Authors not recorded
Science2018PMID 30309915PMC6718162stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerSolid Neoplasmcivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- variantHighcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30309915
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| Pembrolizumab | Solid NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12594This study analyzed over 300 patient with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials to define genomic and immune predictors of response to pembrolizuma… (full text at CIViC) PMID 30309915 · Cristescu et al., 2018 · Open in CIViC | civic |